StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

Equities research analysts at StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the stock.

Aspira Women’s Health Stock Performance

AWH stock opened at $0.70 on Tuesday. The company’s 50 day moving average price is $0.82 and its 200 day moving average price is $1.02. The firm has a market capitalization of $11.71 million, a price-to-earnings ratio of -0.59 and a beta of 1.39. Aspira Women’s Health has a fifty-two week low of $0.67 and a fifty-two week high of $5.65.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.